Medical Pharmacology: Chapter 33 — Anti-Cancer Drugs Part I: Pharmacology -- Module 6 — Miscellaneous Cytotoxics, Drug Interactions, and Supportive Pharmacology

Chapter 33 — Anti-Cancer Drugs Part I: Pharmacology — Module 6 — Miscellaneous Cytotoxics, Drug Interactions, and Supportive Pharmacology

1. Hydroxyurea is used to treat several blood disorders, including sickle cell disease and certain bone marrow cancers. It works by blocking a single enzyme that cells need in order to copy their DNA. Which enzyme does hydroxyurea block?

A) Ribonucleotide reductase, the enzyme that converts the building blocks for RNA into the building blocks needed to make DNA
B) DNA polymerase, the enzyme that links DNA building blocks together into a new strand
C) Thymidylate synthase, the enzyme that produces one specific DNA building block (thymidine)
D) Topoisomerase II, the enzyme that untangles DNA so it can be copied
E) Dihydrofolate reductase, the enzyme that regenerates the active form of folate

ANSWER: A

Rationale:

Hydroxyurea inhibits ribonucleotide reductase (RNR), the rate-limiting enzyme of new DNA synthesis. RNR converts ribonucleoside diphosphates (the building blocks used to make RNA) into deoxyribonucleoside diphosphates (the precursors required to make DNA). The enzyme carries a stable tyrosyl radical in its small subunit that it needs for catalysis; hydroxyurea scavenges that radical and inactivates the enzyme, so the supply of DNA building blocks dries up and DNA synthesis stalls. Because the block is at the level of supplying precursors, cells that are actively copying their DNA are hit hardest.

Option B: Option B is incorrect because hydroxyurea does not act on DNA polymerase; the building blocks are missing, but the polymerase enzyme itself is not the target.
Option C: Option C is incorrect because thymidylate synthase is the target of fluorouracil, not hydroxyurea.
Option D: Option D is incorrect because topoisomerase II is the target of etoposide and anthracyclines, which is a different mechanism entirely.
Option E: Option E is incorrect because dihydrofolate reductase is the target of methotrexate; folate metabolism is unrelated to hydroxyurea's action.

2. Asparaginase is an enzyme given as a drug to treat acute lymphoblastic leukemia (a cancer of immature white blood cells). Unlike most chemotherapy, it does not directly attack the cancer cell's DNA. Instead, it kills leukemia cells by exploiting a weakness in how those cells obtain a specific amino acid. What does asparaginase actually do in the bloodstream?

A) It blocks the leukemia cell's ribosomes so they can no longer assemble proteins
B) It breaks down the amino acid asparagine circulating in the blood, starving leukemia cells that cannot make their own
C) It adds asparagine to the blood, overwhelming the leukemia cells with a toxic surplus
D) It blocks the enzyme the cell uses to copy DNA during division
E) It triggers an immune attack that targets a protein on the leukemia cell surface

ANSWER: B

Rationale:

Asparaginase catalyzes the breakdown (hydrolysis) of the amino acid L-asparagine in the blood into aspartic acid and ammonia, lowering the circulating asparagine concentration. Most normal cells make their own asparagine using an enzyme called asparagine synthetase (ASNS, the cell's internal asparagine factory) and are therefore protected. Many acute lymphoblastic leukemia (ALL) blasts express very little asparagine synthetase and depend on asparagine taken up from the blood; when asparaginase strips that supply away, those cells cannot build the proteins they need and undergo programmed cell death. This is a uniquely tumor-selective strategy because it exploits a specific metabolic deficiency of the cancer cells rather than simply targeting rapid division.

Option A: Option A describes the downstream consequence (protein synthesis fails) but misstates the mechanism — asparaginase does not bind ribosomes; it removes the raw material.
Option C: Option C is incorrect because it states the opposite of what occurs; the drug depletes asparagine rather than adding it.
Option D: Option D describes DNA replication inhibition, which is the mechanism of agents like hydroxyurea, not asparaginase.
Option E: Option E describes a monoclonal antibody mechanism, which is unrelated to this enzyme drug.

3. The cell division cycle has distinct phases: G1 (the cell grows and prepares), S phase (the cell copies its DNA), G2 (a final check), and M phase (the cell physically divides). Because hydroxyurea cuts off the supply of DNA building blocks, it does its greatest damage to cells caught in one particular phase. Which phase makes a cell most vulnerable to hydroxyurea?

A) G1 phase, when the cell is growing but has not yet started copying DNA
B) G2 phase, after DNA copying is finished but before division
C) S phase, when the cell is actively copying its DNA
D) M phase, when the cell is physically pulling apart into two cells
E) G0 phase, when the cell is resting and not dividing at all

ANSWER: C

Rationale:

Hydroxyurea is an S-phase-specific agent. S phase is the part of the cell cycle when DNA is actively being copied, which is precisely when a steady supply of DNA building blocks is required. By blocking ribonucleotide reductase and cutting off that supply, hydroxyurea causes the DNA-copying machinery to stall (replication fork arrest) in cells that are in S phase at the moment of exposure, leading to DNA strand breaks and cell death. Cells in other phases are relatively spared at that instant because they are not actively copying DNA. This S-phase specificity also explains why hydroxyurea, given intermittently, can synchronize a cell population at the boundary between G1 and S — a property used to make tumors more sensitive to radiation.

Option A: Option A is incorrect because in G1 the cell has not yet begun DNA synthesis and so does not yet depend on the blocked precursor supply.
Option B: Option B is incorrect because in G2 DNA copying is already complete.
Option D: Option D is incorrect because M phase is physical division, not DNA synthesis; M-phase-specific drugs are the vinca alkaloids and taxanes.
Option E: Option E is incorrect because resting (G0) cells are not synthesizing DNA and are the least affected.

4. Thalidomide and its relatives lenalidomide and pomalidomide are called immunomodulatory drugs (IMiDs) and are used to treat multiple myeloma (a cancer of plasma cells). Their main anti-cancer action depends on binding to a protein called cereblon (CRBN), which is part of the cell's protein-disposal system. What happens after an IMiD binds cereblon?

A) Cereblon is permanently destroyed, shutting down all protein disposal in the cell
B) Cereblon stops binding the drug and the drug is rapidly cleared from the body
C) Cereblon releases more of two survival proteins, helping the myeloma cell grow
D) Cereblon is redirected to tag two specific transcription factors (Ikaros and Aiolos) for destruction, removing proteins the myeloma cell needs to survive
E) Cereblon begins copying the myeloma cell's DNA at an accelerated rate

ANSWER: D

Rationale:

Cereblon (CRBN) is the substrate-recognition piece of a larger protein-disposal machine (an E3 ubiquitin ligase complex), the system cells use to tag unwanted proteins for destruction. When an IMiD such as thalidomide or lenalidomide binds cereblon, it changes which proteins cereblon grabs: it recruits two transcription factors, Ikaros (IKZF1) and Aiolos (IKZF3), as new targets and tags them for proteasomal degradation. Ikaros and Aiolos normally drive expression of survival and growth genes in myeloma cells, so destroying them reduces myeloma cell proliferation and survival. Their loss in regulatory T cells also releases a brake on the immune system, which contributes to the immunomodulatory effect.

Option A: Option A is incorrect because cereblon is not destroyed; it is repurposed to degrade new targets.
Option B: Option B is incorrect because binding the drug activates this redirection rather than ejecting the drug.
Option C: Option C is incorrect because it states the opposite of the actual effect; the drug removes survival proteins rather than increasing them.
Option E: Option E is incorrect because cereblon has no role in DNA replication; it is part of the protein-disposal system.

5. Beyond its use in cancer, hydroxyurea is the main disease-modifying drug for sickle cell disease, where it reduces the frequency of painful crises. In sickle cell disease, the abnormal sickle hemoglobin (HbS) clumps together and deforms red cells. How does hydroxyurea reduce this sickling?

A) It removes the abnormal sickle hemoglobin gene from red blood cell precursors
B) It thins the blood so sickled cells pass more easily through small vessels
C) It blocks the spleen from removing sickled red cells from circulation
D) It increases the number of red blood cells, diluting the abnormal hemoglobin
E) It raises production of fetal hemoglobin (HbF), which does not sickle and crowds out the abnormal HbS

ANSWER: E

Rationale:

Hydroxyurea raises the production of fetal hemoglobin (HbF), the form of hemoglobin normally made before birth. It does this by reactivating expression of the gamma-globin gene, partly through changes in how that gene is chemically marked and packaged. HbF does not participate in the sickling process, and when more HbF is present inside a red cell, there is proportionally less sickle hemoglobin (HbS) available to clump together and polymerize. The result is fewer vaso-occlusive crises, fewer episodes of acute chest syndrome, and a reduced need for transfusions. This benefit is separate from hydroxyurea's anti-cancer mechanism, though both ultimately trace back to the same drug.

Option A: Option A is incorrect because hydroxyurea does not perform gene editing or remove any gene; the HbS gene remains present.
Option B: Option B is incorrect because hydroxyurea is not an anticoagulant and does not work by thinning the blood.
Option C: Option C is incorrect because it does not act on splenic clearance of red cells.
Option D: Option D is incorrect and in fact backwards: hydroxyurea typically lowers blood counts (it is myelosuppressive) rather than raising the red cell number.

6. The original asparaginase enzyme came from E. coli bacteria, but it had to be injected every few days and frequently triggered immune reactions. Pegaspargase is a modified version in which the enzyme is coated with chains of a polymer called polyethylene glycol (PEG). What is the main practical advantage of this PEG coating?

A) It allows the drug to be taken by mouth instead of by injection
B) It hides the enzyme from the immune system and greatly lengthens its time in the blood, so it can be given far less often
C) It makes the enzyme break down asparagine faster, requiring smaller doses
D) It eliminates the risk of pancreatitis associated with asparaginase therapy
E) It changes the enzyme so it now targets a different amino acid

ANSWER: B

Rationale:

Attaching polyethylene glycol (PEG) chains to the asparaginase enzyme shields its surface from the immune system, which reduces how strongly the body recognizes and attacks it. This shielding dramatically extends the enzyme's half-life — from roughly a day for the native enzyme to about five to seven days for pegaspargase — which means it can be dosed every two to four weeks instead of every few days, and it provokes fewer neutralizing antibodies. Pegaspargase is therefore the standard asparaginase preparation in current leukemia protocols.

Option A: Option A is incorrect because pegaspargase is still given parenterally, not orally; PEGylation does not make a protein drug orally absorbable.
Option C: Option C is incorrect because the PEG coating does not speed up the enzyme's catalytic activity; the benefit is pharmacokinetic (longer duration), not a faster reaction.
Option D: Option D is incorrect because pancreatitis remains a recognized toxicity of asparaginase regardless of PEGylation.
Option E: Option E is incorrect because the enzyme's target is unchanged — it still breaks down asparagine.

7. Many cancer drugs are broken down by a liver enzyme called CYP3A4 (one of the cytochrome P450 enzymes that the liver uses to metabolize drugs). When another drug blocks CYP3A4, the cancer drug is cleared more slowly and builds up to dangerous levels. A leukemia patient on vincristine (which is removed by CYP3A4) is started on the antifungal voriconazole, a strong CYP3A4 blocker. Why is this combination dangerous?

A) Voriconazole blocks the breakdown of vincristine, so vincristine accumulates and can cause severe, potentially fatal nerve damage
B) Voriconazole speeds up the breakdown of vincristine, making the chemotherapy ineffective
C) Voriconazole and vincristine combine to form a toxic compound in the liver
D) Voriconazole prevents vincristine from reaching the tumor by binding it in the blood
E) Voriconazole increases the patient's risk of fungal infection by inactivating vincristine

ANSWER: A

Rationale:

Voriconazole is a potent inhibitor of CYP3A4, the liver enzyme responsible for clearing vincristine. When CYP3A4 is blocked, vincristine is broken down much more slowly, so its blood levels climb at standard doses. Vincristine's dose-limiting toxicity is peripheral neurotoxicity, and the elevated exposure caused by this interaction can produce severe, sometimes fatal neurotoxicity. This is one of the most important and frequently encountered interactions in oncology, because patients receiving chemotherapy are often also on antifungal prophylaxis; the combination requires reducing the vincristine dose or substituting a less potent CYP3A4 inhibitor.

Option B: Option B is incorrect because it states the opposite of what an inhibitor does; voriconazole slows breakdown rather than speeding it, and enzyme inducers like rifampin are the ones that accelerate clearance.
Option C: Option C is incorrect because the danger is not a chemical reaction between the two drugs but slowed metabolism of vincristine.
Option D: Option D is incorrect because the mechanism is reduced clearance, not protein binding that sequesters the drug away from the tumor.
Option E: Option E is incorrect because vincristine has no antifungal role and the interaction does not work by inactivating it.

8. Lenalidomide is closely related to thalidomide but has a striking and almost specific ability to treat one particular condition: a type of myelodysplastic syndrome (a bone marrow disorder) in which the bone marrow cells are missing part of chromosome 5, known as del(5q). This special activity comes from lenalidomide's ability to tag an additional protein for destruction that thalidomide does not. Which extra target explains lenalidomide's effect in del(5q) disease?

A) Ikaros, the same transcription factor that all IMiDs degrade
B) Vascular endothelial growth factor, the signal that drives new blood vessel growth
C) Tumor necrosis factor-alpha, an inflammatory signaling molecule
D) Casein kinase 1-alpha (CK1-alpha), a protein that del(5q) bone marrow cells specifically depend on for survival
E) Cereblon, the protein-disposal adaptor that the drug binds

ANSWER: D

Rationale:

Lenalidomide redirects cereblon to degrade an additional target beyond the Ikaros and Aiolos proteins that all IMiDs degrade: casein kinase 1-alpha (CK1-alpha). The gene for CK1-alpha sits in the region of chromosome 5 that is deleted in del(5q) myelodysplastic syndrome, so these cells already have only one copy and are unusually dependent on the remaining CK1-alpha for survival. When lenalidomide drives degradation of CK1-alpha, del(5q) cells are selectively killed, which is why lenalidomide produces transfusion independence in about two-thirds of these patients and is almost specific for this subtype.

Option A: Option A is incorrect because Ikaros degradation is shared by all IMiDs including thalidomide and does not explain the unique del(5q) activity.
Option B: Option B is incorrect because inhibition of vascular endothelial growth factor (an anti-angiogenic effect of thalidomide-class drugs) is not the basis of the specific del(5q) response.
Option C: Option C is incorrect because reducing tumor necrosis factor-alpha (an anti-inflammatory effect of thalidomide-class drugs) likewise does not explain the del(5q) activity.
Option E: Option E is incorrect because cereblon is the adaptor the drug binds to, not a degraded target; degrading cereblon itself would defeat the mechanism.

9. Chemotherapy-induced peripheral neuropathy (CIPN) is nerve damage — usually numbness, tingling, or pain in the hands and feet — caused by certain cancer drugs. Many treatments have been tried for established CIPN pain, but only one has high-quality randomized trial evidence behind it. Which drug is the recommended first choice for treating painful CIPN?

A) Gabapentin, an anticonvulsant often used for nerve pain
B) Vitamin E supplementation
C) Duloxetine, an antidepressant that also relieves nerve pain
D) Calcium and magnesium infusions given with each chemotherapy dose
E) Topical lidocaine patches applied to the feet

ANSWER: C

Rationale:

Duloxetine is the only agent supported by Level I evidence (a positive randomized controlled trial, the ACCRU/Alliance trial) for treating established painful chemotherapy-induced peripheral neuropathy, and it is the recommended first-line pharmacologic treatment. It is typically started at 30 mg daily and titrated to 60 mg daily. Duloxetine is a serotonin-norepinephrine reuptake inhibitor, a class of antidepressant that also dampens pain signaling in nerve pathways.

Option A: Option A is incorrect because gabapentin, despite being widely used for other neuropathic pain, has shown only equivocal results in CIPN trials and is considered a possible alternative rather than the evidence-based first choice.
Option B: Option B is incorrect because vitamin E has not shown consistent benefit and is not recommended.
Option D: Option D is incorrect because calcium/magnesium infusions were tested for preventing oxaliplatin neuropathy and failed in a randomized trial, so they are no longer recommended — and they are a prevention strategy, not a treatment for established pain.
Option E: Option E is incorrect because topical agents such as lidocaine have weak and inconsistent evidence and are not the recommended first-line treatment.

10. Taxanes such as paclitaxel are chemotherapy drugs that work by stabilizing microtubules — the internal protein tracks inside cells. In nerve cells, these same microtubules serve as transport rails that carry cargo along the length of very long nerve fibers (axons). Why does stabilizing microtubules cause the numbness and tingling of taxane-induced neuropathy, and why does it strike the hands and feet first?

A) Taxanes dissolve the protective myelin sheath around nerves, exposing them to damage
B) Taxanes cause nerves to fire uncontrollably, producing constant pain signals
C) Taxanes cut off the blood supply to the nerves in the extremities
D) Taxanes trigger an autoimmune attack specifically against sensory nerves
E) Taxanes freeze the microtubule tracks so cargo can no longer move along the axon, and the longest nerves reaching the hands and feet fail first

ANSWER: E

Rationale:

Taxanes stabilize microtubules so completely that the microtubules become rigid and non-dynamic. In a nerve cell, microtubules are the rails along which mitochondria, signaling molecules, and other essential cargo are transported up and down the axon. When the rails are frozen, this transport breaks down, the far end of the axon is starved of what it needs, and the axon degenerates from its tip backward. The nerves that reach the hands and feet are the longest in the body, so they are the most dependent on intact transport and the first to fail — producing the classic stocking-glove pattern of numbness beginning in the fingers and toes.

Option A: Option A is incorrect because taxanes do not strip myelin; the injury is to the axon and its internal transport, not the myelin sheath.
Option B: Option B is incorrect because the problem is degeneration of the axon, not runaway electrical firing.
Option C: Option C is incorrect because the mechanism is failed intracellular transport, not loss of blood supply.
Option D: Option D is incorrect because taxane neuropathy is a direct toxic effect on the axon, not an autoimmune attack.

11. Thalidomide caused one of the worst drug disasters in history when it was given to pregnant women in the 1950s, producing thousands of children with severe limb malformations. Today thalidomide and its relatives lenalidomide and pomalidomide are valuable cancer drugs, but they carry the same danger. Because of this, how are these drugs distributed in the United States?

A) They are available without restriction since modern dosing has eliminated the birth-defect risk
B) Only through mandatory risk-management (REMS) programs that require pregnancy testing, contraception counseling, and prescriber and pharmacy registration before the drug can be dispensed
C) Only in hospitals, where they may be given to any patient including pregnant women under supervision
D) Only to male patients, since the risk applies exclusively to female patients
E) Only after the patient signs a waiver releasing the manufacturer from liability, with no testing required

ANSWER: B

Rationale:

Thalidomide, lenalidomide, and pomalidomide remain among the most powerful human teratogens known, and a single dose at a vulnerable point in pregnancy can cause severe limb malformations. To prevent fetal exposure, they are distributed only through federally mandated Risk Evaluation and Mitigation Strategy (REMS) programs — a controlled-distribution system required by the FDA. These programs require confirmed negative pregnancy testing before and during treatment for women of childbearing potential, counseling on using two reliable forms of contraception, and registration of the prescriber, the pharmacy, and the patient before the drug can be dispensed.

Option A: Option A is incorrect because the teratogenic risk has not been eliminated; it is the very reason for the restrictions.
Option C: Option C is incorrect because the drugs are absolutely contraindicated in pregnancy and the controls exist specifically to keep them away from pregnant patients.
Option D: Option D is incorrect because the controls apply to all patients; in fact male patients must also use condoms because the drug appears in semen, so the risk is not limited to one sex.
Option E: Option E is incorrect because a liability waiver does not substitute for the mandatory testing and registration the REMS program requires.

12. Oxaliplatin, a platinum chemotherapy drug used for colon cancer, causes an unusual nerve effect that is different from the slow, cumulative numbness of most chemotherapy. Patients are warned not to touch cold objects or drink cold liquids in the days after each infusion. What is this distinctive oxaliplatin effect?

A) An acute, cold-triggered sensation of tingling or discomfort in the hands, feet, and around the mouth that appears soon after infusion
B) A permanent loss of the sense of taste triggered by cold foods
C) Sudden severe high blood pressure whenever the patient is exposed to cold
D) A drop in body temperature that requires external warming after each dose
E) Cold-induced destruction of red blood cells leading to anemia

ANSWER: A

Rationale:

Oxaliplatin produces a characteristic acute, cold-triggered sensory syndrome: within hours to days of an infusion, exposure to cold provokes tingling, prickling, or uncomfortable sensations (paresthesias and dysesthesias) in the hands, feet, and the region around the mouth. It occurs in the large majority of patients after infusions and is caused by cold-induced changes in how sodium channels behave in sensory nerves — a mechanism distinct from the slow, cumulative neuropathy that platinum drugs also cause over many cycles. Because it is triggered by cold, patients are counseled to avoid cold drinks, cold air, and handling cold objects in the days following treatment.

Option B: Option B is incorrect because the syndrome is a sensory nerve phenomenon, not a permanent loss of taste.
Option C: Option C is incorrect because it is not a blood-pressure reaction.
Option D: Option D is incorrect because oxaliplatin does not lower core body temperature.
Option E: Option E is incorrect because this is a nerve effect, not cold-induced breakdown of red blood cells.

13. Tamoxifen is a drug used for hormone-receptor-positive breast cancer, but it is actually a prodrug: it must be converted by a liver enzyme called CYP2D6 into its active form, endoxifen, to work properly. A woman taking tamoxifen becomes depressed, and her physician is considering an antidepressant. Why might paroxetine be a poor choice for this patient?

A) Paroxetine speeds up tamoxifen breakdown, lowering its blood levels
B) Paroxetine and tamoxifen combine to form a compound that is toxic to the liver
C) Paroxetine blocks tamoxifen from binding to the breast cancer cells
D) Paroxetine strongly blocks CYP2D6, reducing the conversion of tamoxifen to its active form endoxifen and potentially weakening tamoxifen's anti-cancer effect
E) Paroxetine increases tamoxifen levels to a dangerous degree, raising the risk of toxicity

ANSWER: D

Rationale:

Tamoxifen depends on the liver enzyme CYP2D6 to convert it into endoxifen, the metabolite that actually carries most of its anti-cancer activity. Paroxetine is one of the most potent CYP2D6 inhibitors among the antidepressants; by blocking that enzyme, it can cut endoxifen levels substantially and potentially undermine the effectiveness of adjuvant tamoxifen therapy. For this reason, a CYP2D6-sparing antidepressant such as venlafaxine, citalopram, or escitalopram is preferred in patients taking tamoxifen for breast cancer.

Option A: Option A is incorrect because paroxetine inhibits rather than speeds up the relevant enzyme, and the concern is reduced activation, not faster clearance of the parent drug.
Option B: Option B is incorrect because the issue is impaired metabolic activation, not a toxic combined compound.
Option C: Option C is incorrect because paroxetine does not interfere with tamoxifen binding to its receptor; it interferes with making the active metabolite.
Option E: Option E is incorrect and backwards: the problem is too little active drug (endoxifen), not dangerously high tamoxifen levels.

14. A patient with multiple myeloma is started on lenalidomide combined with dexamethasone, a common regimen. Beyond watching for low blood counts, the team must take a specific preventive step at the start of this therapy because of a well-known risk. What must be started?

A) A daily proton pump inhibitor to prevent stomach ulcers
B) Routine antifungal prophylaxis to prevent invasive fungal infection
C) Thromboprophylaxis (a blood-clot-preventing drug such as aspirin or low-molecular-weight heparin) because lenalidomide markedly raises the risk of venous blood clots
D) An anti-seizure medication to prevent neurotoxicity
E) Calcium and vitamin D to prevent the bone loss caused by lenalidomide

ANSWER: C

Rationale:

Lenalidomide substantially increases the risk of venous thromboembolism (blood clots in the veins, such as deep vein thrombosis and pulmonary embolism), and that risk rises further when it is combined with dexamethasone or with doxorubicin. For this reason, thromboprophylaxis is mandatory when starting lenalidomide-based therapy: lower-risk patients typically receive aspirin, while higher-risk patients receive low-molecular-weight heparin or warfarin.

Option A: Option A is incorrect because routine ulcer prophylaxis is not a defining requirement of lenalidomide therapy.
Option B: Option B is incorrect because antifungal prophylaxis is driven by the degree of immunosuppression and neutropenia in a given regimen, not specifically mandated by lenalidomide itself.
Option D: Option D is incorrect because lenalidomide is actually less neurotoxic than thalidomide and does not require seizure prophylaxis.
Option E: Option E is incorrect because bone loss is not the characteristic lenalidomide risk that drives a mandatory preventive measure; the clotting risk is.

15. Asparaginase does more than break down asparagine: because the liver uses asparagine to build many proteins, asparaginase therapy lowers the production of several proteins made by the liver. Among these are clotting factors and the natural anticoagulants that normally keep clotting in balance. What clinical consequence does this protein depletion produce?

A) Only an increased risk of bleeding, because clotting factors fall
B) Only an increased risk of clotting, because anticoagulants fall
C) High blood pressure from fluid retention
D) Liver failure from accumulation of asparagine
E) A disturbed balance of clotting that can cause either dangerous clots or bleeding, including clots in the brain's venous sinuses

ANSWER: E

Rationale:

Asparaginase reduces the liver's output of many proteins, including both pro-clotting factors (such as fibrinogen) and the natural anticoagulants that restrain clotting (such as antithrombin III and protein C). Because both sides of the clotting balance are depleted, the net effect varies from patient to patient and can tip toward either dangerous clot formation or bleeding. A particularly serious complication is central venous sinus thrombosis — a clot in the large veins draining the brain — which can present with headache, altered consciousness, focal neurological deficits, and seizures.

Option A: Option A is incorrect because it captures only the bleeding side and misses the prominent thrombotic risk.
Option B: Option B is incorrect because it captures only the clotting side and misses the bleeding risk.
Option C: Option C is incorrect because asparaginase does not characteristically cause hypertension from fluid retention.
Option D: Option D is incorrect because, although asparaginase can cause hepatotoxicity, the protein-depletion mechanism described here produces a clotting imbalance rather than liver failure from accumulated asparagine.

16. One long-term price of curing cancer with chemotherapy is that some treatments can later cause a second, treatment-related blood cancer (a treatment-related myeloid neoplasm). Alkylating agents such as cyclophosphamide cause a characteristic form of this. Which description fits alkylating-agent-related secondary leukemia?

A) A long latency of roughly 5 to 10 years, often preceded by a phase of bone marrow failure (myelodysplasia), with loss of material from chromosomes 5 or 7
B) A short latency of 1 to 3 years, appearing suddenly as full-blown leukemia with no warning phase
C) No latency at all, appearing within weeks of the first dose
D) A latency of decades, occurring only after age 80 regardless of dose
E) A form that always resolves on its own without treatment

ANSWER: A

Rationale:

Alkylating-agent-related secondary leukemia follows a recognizable pattern. The latency from exposure to diagnosis is long — typically about 5 to 10 years — and the disease usually announces itself first as a period of failing, dysfunctional bone marrow (myelodysplastic syndrome) before it transforms into acute leukemia. The characteristic chromosomal findings are loss of genetic material from chromosomes 5 or 7 (such as monosomy 5/del(5q) or monosomy 7/del(7q)), reflecting loss of tumor-suppressor genes that normally regulate blood-cell production.

Option B: Option B describes the contrasting pattern caused by topoisomerase II inhibitors (short latency, abrupt onset as frank leukemia), not alkylating agents.
Option C: Option C is incorrect because secondary leukemia does not appear within weeks; it requires years to develop.
Option D: Option D is incorrect because the latency is years, not decades, and is not restricted to advanced age; the risk is dose-dependent.
Option E: Option E is incorrect because these secondary leukemias do not resolve spontaneously and in fact carry a poor prognosis.

17. Topoisomerase II inhibitors — drugs such as etoposide and the anthracyclines — can also cause a treatment-related leukemia, but it looks quite different from the kind caused by alkylating agents. Which description fits topoisomerase II inhibitor-related secondary leukemia?

A) A long latency of 5 to 10 years preceded by a prolonged phase of bone marrow failure
B) A short latency of about 1 to 3 years, appearing directly as acute leukemia without a preceding myelodysplastic phase, often with a rearrangement of the KMT2A gene on chromosome 11q23
C) Loss of material from chromosomes 5 and 7 after a decade of latency
D) A leukemia that appears only after the patient has also received an alkylating agent
E) A benign blood count abnormality that never progresses to leukemia

ANSWER: B

Rationale:

Topoisomerase II inhibitor-related secondary leukemia has a strikingly different profile from the alkylating-agent type. Its latency is short — usually about 1 to 3 years — and it typically appears directly as acute myeloid leukemia without first passing through a myelodysplastic (failing-marrow) phase. Its genetic hallmark is a balanced rearrangement (translocation) involving the KMT2A gene on chromosome 11q23, which arises because these drugs trap the topoisomerase II enzyme on DNA at specific sites and directly generate the rearrangement.

Option A: Option A describes the alkylating-agent pattern (long latency, preceding myelodysplasia), which is the opposite of this type.
Option C: Option C is incorrect because it describes the alkylating-agent chromosomal findings (loss from chromosomes 5 and 7) and the wrong latency.
Option D: Option D is incorrect because topoisomerase II inhibitor-related leukemia does not require prior alkylating-agent exposure; either class can cause secondary leukemia independently.
Option E: Option E is incorrect because this is a true acute leukemia, not a harmless lab finding.

18. A pregnant woman is newly diagnosed with cancer. The timing of chemotherapy relative to the stage of pregnancy strongly affects the risk to the fetus. Which statement best reflects the established principle for giving cytotoxic chemotherapy during pregnancy?

A) Chemotherapy is safest in the first trimester, when the fetus is small and well protected
B) Chemotherapy is equally risky throughout all three trimesters
C) Chemotherapy can be given right up to the day of delivery with no special precaution
D) Chemotherapy is contraindicated in the first trimester because that is the critical window of organ formation, while many regimens can be given more safely in the second and third trimesters
E) Only oral chemotherapy crosses the placenta, so intravenous drugs are always safe in pregnancy

ANSWER: D

Rationale:

The first trimester is the period of organogenesis — when the fetus's major organs and structures are forming — and it is the window of greatest vulnerability to structural birth defects. For this reason essentially all cytotoxic chemotherapy is contraindicated in the first trimester, and the rate of miscarriage is also higher. After the first trimester, many regimens have been given in the second and third trimesters with acceptable outcomes, though antimetabolites such as methotrexate remain relatively contraindicated throughout pregnancy.

Option A: Option A is incorrect and dangerously backwards: the first trimester is the most hazardous time, not the safest.
Option B: Option B is incorrect because risk is not uniform; it is concentrated in the first trimester.
Option C: Option C is incorrect because chemotherapy should be stopped several weeks before anticipated delivery to let mother and fetus clear the drug and to reduce newborn bone marrow suppression.
Option E: Option E is incorrect because the route of administration does not determine placental transfer; many intravenous agents cross the placenta.

19. Earlier in this set you learned that taxanes cause neuropathy by freezing the transport rails inside long nerve fibers. Platinum drugs such as cisplatin also cause a sensory neuropathy, but they injure a different part of the nervous system. Where do platinum compounds primarily do their damage?

A) The myelin sheath wrapping the nerve fibers
B) The motor nerves controlling muscle movement
C) The sensory nerve cell bodies clustered just outside the spinal cord (the dorsal root ganglia), where platinum accumulates and damages the cells' DNA
D) The transport rails (microtubules) inside the axon, exactly as taxanes do
E) The brain's pain-processing centers rather than the peripheral nerves

ANSWER: C

Rationale:

Platinum compounds such as cisplatin and oxaliplatin primarily injure the sensory nerve cell bodies that sit in clusters just outside the spinal cord, called the dorsal root ganglia (DRG). Platinum accumulates in these cell bodies and forms platinum-DNA adducts — platinum bound directly to the cell's DNA — which damages the neurons and triggers their death, producing a sensory neuropathy. This is a different target from the taxanes: taxanes freeze the microtubule transport rails inside the axon (the mechanism covered earlier in this set), whereas platinum drugs strike the sensory cell body itself.

Option A: Option A is incorrect because platinum injury is to the sensory neuron, not the myelin sheath.
Option B: Option B is incorrect because platinum neuropathy is predominantly sensory rather than motor.
Option D: Option D is incorrect because it restates the taxane mechanism, which is precisely what distinguishes taxanes from platinum drugs.
Option E: Option E is incorrect because the damage is to peripheral sensory neurons, not central brain pain centers.

20. Earlier you saw that an enzyme blocker (voriconazole) can make a chemotherapy drug build up to toxic levels. The opposite problem also exists: some drugs are enzyme inducers, meaning they make the liver produce more CYP3A4 and clear other drugs faster. A patient on the targeted cancer drug imatinib (cleared by CYP3A4) is started on rifampin, a strong CYP3A4 inducer, to treat tuberculosis. What is the likely consequence?

A) Imatinib levels rise sharply, causing severe toxicity
B) The two drugs combine to form a compound toxic to the kidneys
C) Rifampin has no effect on imatinib because they act on different enzymes
D) Imatinib blocks rifampin, allowing the tuberculosis to worsen
E) Imatinib levels fall substantially because rifampin speeds its breakdown, risking loss of cancer control

ANSWER: E

Rationale:

Rifampin is a potent inducer of CYP3A4 — it prompts the liver to make much more of the enzyme that clears imatinib. With more enzyme present, imatinib is broken down faster and its blood concentration falls substantially (its exposure can drop by roughly 70%), which risks loss of disease control. Management requires increasing the imatinib dose or, preferably, substituting an alternative anti-tuberculosis drug that does not induce CYP3A4.

Option A: Option A is incorrect and backwards: an inducer lowers drug levels, whereas an inhibitor like voriconazole raises them.
Option B: Option B is incorrect because the problem is accelerated metabolism, not formation of a kidney-toxic compound.
Option C: Option C is incorrect because both drugs interact through the same enzyme, CYP3A4 — rifampin induces it and imatinib is cleared by it.
Option D: Option D is incorrect because imatinib does not block rifampin's antitubercular action; the interaction runs the other way, with rifampin reducing imatinib levels.

21. Clinicians grade the severity of chemotherapy-induced peripheral neuropathy on a scale (the CTCAE scale) running from Grade 1 (mild, with findings but no symptoms limiting activity) up to Grade 4 (life-threatening). This grading is not just descriptive — it guides whether to continue, reduce, or stop the neurotoxic drug. Which principle correctly links neuropathy grade to dose decisions?

A) As neuropathy worsens from mild to severe, the response escalates from no change, to dose reduction, to discontinuing the offending drug — and severe (Grade 3 to 4) neuropathy calls for stopping the neurotoxic agent
B) The drug should be stopped at the very first sign of any Grade 1 neuropathy, regardless of severity
C) The dose should be increased as neuropathy worsens, to overpower the tumor before more damage occurs
D) Neuropathy grade is ignored in dosing decisions, which are based only on tumor response
E) Only Grade 4 neuropathy ever warrants any change, and all lower grades are treated identically with no adjustment

ANSWER: A

Rationale:

Neuropathy grading drives a graded response. Mild (Grade 1) neuropathy generally does not require a dose change but is documented and watched for worsening; moderate (Grade 2) neuropathy in a curative regimen typically prompts a dose reduction and reassessment; and severe (Grade 3 to 4) neuropathy calls for discontinuing the offending neurotoxic agent, substituting a less neurotoxic alternative when the regimen allows. The balance also depends on goals of care — there is less tolerance for persistent severe neuropathy when treatment is palliative and quality of life is the priority.

Option B: Option B is incorrect because Grade 1 neuropathy does not by itself require stopping the drug; that would needlessly compromise treatment.
Option C: Option C is incorrect and dangerous: worsening neuropathy calls for reducing or stopping the drug, never increasing it.
Option D: Option D is incorrect because neuropathy grade is a central input into dose modification, not something ignored.
Option E: Option E is incorrect because meaningful action begins well before Grade 4 — Grade 2 and Grade 3 already prompt reduction or discontinuation.

22. A recurring theme across this chapter is that each chemotherapy class carries its own signature organ toxicity, and some of these toxicities depend on the total dose received over a lifetime. For the anthracyclines such as doxorubicin, what is the characteristic dose-dependent toxicity that must be tracked across all of a patient's prior treatment?

A) Pulmonary fibrosis, a progressive scarring of the lungs
B) Cumulative cardiomyopathy — heart muscle damage whose risk rises with the total lifetime dose received, requiring that prior anthracycline exposure be tracked and heart function monitored
C) Permanent kidney failure after a single dose
D) Hemorrhagic cystitis, bleeding from the bladder lining
E) Hearing loss that appears immediately after the first infusion

ANSWER: B

Rationale:

The anthracyclines, such as doxorubicin, are defined by cumulative cardiomyopathy: damage to the heart muscle whose risk climbs as the total lifetime dose accumulates. Because the risk is tied to cumulative exposure, clinicians must add up doxorubicin-equivalent doses from all prior treatments and monitor heart function (for example, with measurements of the heart's pumping fraction) before and during therapy. This is why anthracyclines carry lifetime cumulative dose limits — a defining feature of oncology practice.

Option A: Option A is incorrect because pulmonary fibrosis is the signature toxicity of bleomycin, not anthracyclines.
Option C: Option C is incorrect because the characteristic anthracycline toxicity is cardiac and cumulative, not single-dose kidney failure; nephrotoxicity is more characteristic of cisplatin.
Option D: Option D is incorrect because hemorrhagic cystitis is the signature bladder toxicity of cyclophosphamide and ifosfamide, not anthracyclines.
Option E: Option E is incorrect because hearing loss is the ototoxicity associated with cisplatin and is not the cumulative, dose-tracked cardiac toxicity that anthracyclines are known for.